Majority stockholder approves reverse stock split of FOXO common stock at ratio up to 1:500

FOXO TECHNOLOGIES INC.

Rennova Health (controlled by CEO) holds 60% voting rights, approved reverse split via written consent on Sept 2, 2025.
Reverse split ratio from 1:10 to 1:500; Board will set exact ratio, must act by July 31, 2026.
Company to file preliminary Schedule 14C; reverse split effective 20 days after mailing definitive statement.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.